| George Boris Mychaliska, MD | |
|
1500 E Medical Center Dr Fl 4, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | George Boris Mychaliska |
|---|---|
| Gender | Male |
| Speciality | Surgery - Pediatric Surgery |
| Location | 1500 E Medical Center Dr Fl 4, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881796118 | NPI | - | NPPES |
| 4677482 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 4301074649 (Michigan) | Secondary |
| 2086S0120X | Surgery - Pediatric Surgery | 4301074649 (Michigan) | Primary |
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
| Entity Name | Hurley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982630844 PECOS PAC ID: 2961308481 Enrollment ID: O20031208000375 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
| Entity Name | Edward W Sparrow Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831139088 PECOS PAC ID: 6709799166 Enrollment ID: O20040102000790 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
| Entity Name | St Joseph Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659499705 PECOS PAC ID: 3779489281 Enrollment ID: O20040226001002 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
| Entity Name | Sjmh Medical Practice-smhc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346284684 PECOS PAC ID: 8628965175 Enrollment ID: O20040301000770 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| George Boris Mychaliska, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | George Boris Mychaliska, MD 1500 E Medical Center Dr Fl 4, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
A potential new biomarker for heart failure may be more powerful than established measures in identifying patients at increased risk for death from several causes.
Doctor Elena Zubillaga studied 109 women and 120 men admitted to hospital with a cardiac insufficiency solely due to high blood pressure. More concretely, she analysed the clinical, biochemical and ecocardiographical differences between the patients, depending on their sex. She also made reference to the data provided by serum markers for the metabolism of the collagen in the heart and the systolic function or contraction of the latter, as alterations taking place in the metabolism of myocardial collagen are associated with certain clinical situations.
Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.
› Verified 6 days ago
John C Magee, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Steven W Bruch, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr., 4th Floor, C.s. Mott Children's Hospital, Ann Arbor, MI 48109 Phone: 734-764-4151 | |
Theodore Hobart Welling, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, 2nd Floor Taubman Ctr Recp F, Ann Arbor, MI 48109 Phone: 734-936-5738 | |
Eiichi A Miyasaka, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Department Of Surgery, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Nathan Louras, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Robert J Beaulieu, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Meredith Barrett, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 |